Megan Hollasch

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication OncologyLive, aiding in all aspects of the publication process, as well as content for OncLive.com.

Articles

Quad Shot Radiation Plus Immunotherapy Improves Local Control in Advanced Head and Neck Cancer

March 16th 2024

Quad Shot radiation plus a checkpoint inhibitor significantly improved local control vs Quad Shot alone and was well tolerated as a palliative treatment for patients with advanced head and neck cancer.

Post-Hoc Analysis Shows Dose-Escalated Radiation is Safe and Efficacious in Intrahepatic Cholangiocarcinoma

March 15th 2024

A post-hoc analysis showed dose escalation of radiation therapy was safe and elicited similar efficacy in intrahepatic cholangiocarcinoma.

Advanced Radiation Techniques Could Aid in Cardiac Sparing in Lung, Breast, and Esophageal Cancer Treatment

March 15th 2024

Charles B. Simone II, MD, FASTRO, FACRO, discusses advanced radiation techniques that could reduce cardiac toxicities.

Deep Dive into a Case Study on Liver-Sparing TBI Plus Helical Tomotherapy in Relapsed Pre-B Cell ALL

March 15th 2024

A case study of a patient with pre-B cell acute lymphoblastic leukemia showed helical tomotherapy with IMRT-based TBI is a viable option for organ sparing.

Retrospective Study Shows Neoadjuvant SCRT is Associated With Optimal Surgical Outcomes in Rectal Cancer

March 14th 2024

Prolonged duration from neoadjuvant SCRT to surgery did not increase the risk of poor mesorectum specimen quality or post-operative morbidity in rectal cancer.

Brown Details the Evolving Role of PCI and HA-PCI in Small Cell Lung Cancer

March 14th 2024

Paul D. Brown, MD, gives a history of prophylactic cranial irradiation in small cell lung cancer and describes its standing in the treatment paradigm.

PRMT5 Inhibitors Plus Antiestrogens May Combat Resistance to CDK4/6 Inhibitors in ER+ Breast Cancer

March 8th 2024

PRMT5 inhibitors with antiestrogens represents a therapeutic strategy that may overcome resistance to CDK4/6 inhibitors in ER+/RB-deficient breast cancer.

The Billion Dollar Question in Ovarian Cancer: What Therapies to Use for Maintenance and Recurrence

March 7th 2024

PARP inhibitors have shown promise in ovarian cancer treatment, but certain subgroups of patients have few effective options following disease progression.

Clinicians Report Unmet Needs Regarding Training Fellows for Community-Based Careers

March 6th 2024

Clinicians say that there are substantial unmet needs in terms of deliberately training hematology/oncology fellows for community-based careers.

New Clinical Practice Guideline Provides Overview on Salvage Therapy’s Role in Prostate Cancer

March 1st 2024

The American Urological Association has released their 2024 clinical practice guideline on salvage therapy for prostate cancer.

Tackling All Questions ADC: How These Agents Are Joining a Treatment Revolution in NSCLC

February 26th 2024

Benjamin Philip Levy, MD, details how antibody-drug conjugates are shifting the HER2-mutated non–small cell lung cancer treatment paradigm.

Currently Enrolling Trial Examines Innovative Approach in Inflammatory Breast Cancer

February 21st 2024

The S1706 study is currently enrolling patients with inflammatory breast cancer to determine if adding a PARP inhibitor to radiation therapy is effective.

Jagsi Holds a Magnifying Glass to Radiation Oncology: Uncovering Key Disparities and When to Omit Radiation in Breast Cancer

February 16th 2024

Investigating when radiation therapy can be appropriately omitted and striving to uncover disparities are areas of focus in the field of radiation oncology.

Are Higher Standards for Expedited FDA Approvals Needed?

February 15th 2024

Many clinicians have reported a lack of understanding of the FDA approval process and a desire for strong premarket evidence to support these approvals.

ONC201 Looks to Prove Efficacy in Trial For Rare H3K27M-Mutated Diffuse Midline Gliomas

February 14th 2024

The dopamine receptor D2 antagonist ONC201 is under evaluation in patients with H3K27M-mutated diffuse midline glioma in the phase 3 ACTION trial.

Omission in Breast Cancer: When to Leave Radiation Behind and How to Mitigate Disparities

February 12th 2024

Reshma Jagsi, MD, DPhil, details advances from 2023 in breast cancer radiation oncology and interventions aimed at combating disparities within oncology.

Dhruva Details How Physicians Can Learn More About the FDA Approval Process

February 8th 2024

Dhruva explains how physicians reported a lack of understanding when it comes to the FDA approval process, especially regarding expedited approval pathways.

Diving Into Adjuvant Approaches in Early-Stage Resectable NSCLC: PD-L1 Expression and Genomic Considerations

February 6th 2024

Corey J. Langer, MD, FACP, discusses findings from the IMpower010 and KEYNOTE-091 studies, which examined immunotherapy in NSCLC.

Enasidenib Plus Venetoclax Yields High Response Rates Targeting IDH2 Mutations in R/R AML

February 5th 2024

The combination of the first-in-class inhibitor enasidenib plus venetoclax has generated excitement targeting IDH2 mutations in relapsed/refractory AML.

Lonial Spotlights CAR T-Cell and Off-the-Shelf Treatments in Multiple Myeloma

February 2nd 2024

Sagar Lonial, MD, FACP, details how CAR T-cell therapies and off-the-shelf treatments are improving outcomes for patients with multiple myeloma.